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Effects of intrathecal injection of rapamycin
on pain threshold and spinal cord glial
activation in rats with neuropathic pain
Jing Lv, Zhenci Li, Shouzhang She, Lixin Xu, Yanlu Ying
Department of Anesthesiology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou,
Guangdong, China
Objective: To evaluate the effects of intrathecal injection of rapamycin on pain threshold and spinal cord
glial activation in rats with neuropathic pain.
Methods: Healthy 30 male Sprague Dawley (SD) rats were randomly divided into six groups (n55 in each
group): (1) control groupwithout any treatments; (2) chronic constriction injury (CCI) group; (3) Early-rapamy-
cingroupwith intrathecal injectionof rapamycin 4hours afterCCIdays; (4) Early-vehiclegroupwith intrathecal
injection of dimethyl sulphoxide (DMSO); (5) Late-rapamycin group with intrathecal injection of rapamycin
7 days after CCI; (6) Late-vehicle group with intrathecal injection of DMSO 7 days after CCI. Rapamycin or
DMSO was injected for 3 consecutive days. Mechanical and thermal threshold were tested before and
after the CCI operation. Lumbar segment of spinal cords was tested for glial fibrillary acidic protein (GFAP)
by immuohistochemistry on 14th day after operation.
Results:Mechanical and thermal hyperalgesia emergedon fourth dayweremaintained till fourteenthdayafter
operation. After intrathecal injection of rapamycin 4 hours or 7 days after CCI, mechanical and thermal
threshold significantly increased compared to injection of DMSO. The area of GFAP positive and the mean
density of GFAP positive area in the dorsal horn of the ipsilateral side greatly increased in rapamycin-treated
groups.
Conclusions: Intrathecal injection of rapamycin may attenuate CCI-induced hyperalgesia and inhibit the acti-
vation of astrocyte.
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Introduction
Neuropathic pain has pain hypersensitivity proper-
ties, such as spontaneous pain, hyperalgesia and allo-
dynia.1 Previous evidence showed that this
hypersensitivity might be associated with neuronal
plasticity including both peripheral and spinal neur-
onal circuits.2 Neuropathic pain caused by injury or
disease is associated with peripheral or central
nerve system. The original injury is usually healed
without visible tissue damage. Shortly after the
injury, the pain is paroxysmal with abnormal sen-
sation, spontaneous pain and relentless pain caused
by normally non-painful stimuli (allodynia) or
increased long-term sensitivity to pain caused by
mild painful stimuli (hyperalgesia).3 The mammalian
target of rapamycin (mTOR) is a highly conserved
serine/threonine protein kinase that widespread
throughout the nervous system. Recent study
showed that mTOR is closely related with pain sen-
sation and participates in regulating synaptic plas-
ticity change.4 Two distinct mTOR complexes,
mTORC1 and mTORC2, were found in the cells.
The difference was characterised by different com-
ponents and their functions.5
It is reported that mTORC1 regulated the protein
translation process by phosphorylating the down-
stream proteins, such as eukaryotic initiation factor
4E-binding protein 1 (4EBP1) and p70 ribosomal
S6 protein kinase (p70S6K).6 Recently, a direct role
of mTOR in the modulation of glial functions has
also been identified and previous studies revealed
that mTOR is involved in microglial proinflamma-
tory activation.7 Rapamycin is an mTORC1 inhibi-
tor that can block mTORC1 activity and
downstream targets.8 Recent studies showed that
the intrathecal administration of rapamycin could
alleviate the symptoms of neuropathic pain including
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the increased mechanical hypersensitivity.9,10 In this
study, we have focussed on the effect of intrathecal
injection of rapamycin on the pain-related behaviour
and activation of astrocyte in the spinal cord dorsal
horn of chronic constriction injury (CCI) rat
model. Our investigation on the function of mTOR
during the development and maintenance of neuro-
pathic pain might provide theoretical basis for disco-
vering new target in neuropathic pain treatment.
Materials and Methods
Experimental animals and drugs
This work was approved by the Ethic Committee of
Guangzhou First People’s Hospital. Adult male
Sprague Dawley (SD) rat weighing 220–260 g, pro-
vided by the Laboratory Animal Centre of Guang-
dong province, were maintained in a light-
controlled room (lights on from 7:00 a.m. to 7:00
p.m.) at a constant temperature of 26+2uC.
Chronic constriction injury
Chronic constriction of the sciatic nerve was per-
formed according to the method described by Ben-
nett.11 Briefly, rats were anaesthetised with 10%
chloral hydrate (300–350 mg/kg, i.p.) for surgical
procedures. The left sciatic nerve was exposed at
the level of the mid-thigh. Four ligatures (4–0 chro-
mic gut, Ethicon, Rome, Italy) were tied loosely
around the sciatic nerve with a 1.0 mm interval
between each ligature. There should be a slight
vibration in the calf muscles without affecting the
blood supply in the outer membrane. The wound
was then closed in layers.
Rapamycin solution
Rapamycin (R5000-50MG) was purchased from LC
Laboratories (USA) and was dissolved in 4%
DMSO diluted in saline. The working concentration
was 1 mg/ml and stored at 4uC.
Intrathecal catheterisation and drug delivery
Micro spinal catheter was implanted in the lumbosa-
cral cord according to modified Yaksh’s method.12
Rats were anaesthetised with 10% chloral hydrate
(300–350 mg/kg, i.p.) and were laid on the surgical
board in prone position. An incision was made
through skin and fascia above the basilar clivus.
Blunt separation of muscles was performed to
expose the atlanto-occipital membrane and pierce
with syringe needle so that cerebral solution gushed
from the hole and vibrated with the breath. Implant
the polyurethane micro spinal catheter into lumbar
slowly through the wound. The catheter was 7.5–
8 cm in length and was fixed by connecting with a
1.5 cm length polyethylene. The wound was closed
in layers after the surgery. Intramuscular injection
of penicillin on the right upper limb was performed
to prevent infection. Paralysis of both lower limbs
within 30 seconds occurred after injection intrathe-
cally through the catheter with 20 ml of 2% lidocaine,
and then disappeared after 30 minutes, indicating a
successful intrathecal catheterisation. Those with sen-
sory and motor disturbance, such as monoplegia,
paraplegia or hemiplegia, were excluded 2 days
after the catheterisation.
Intrathecal injection of rapamycin (10 mg/10 ml)
4 hours after CCI was performed for consecutive
3 days (once a day) in the early-rapamycin
group. The same operation was performed on the
early-vehicle group with injection of 10 ml 4%
DMSO instead of rapamycin. Intrathecal injection
of rapamycin 10 mg/10 ml or 10 ml 4% DMSO were
performed in the late-rapamycin group and late-
vehicle group, respectively, every day from seventh
to ninth day after CCI. Rats without any treatments
were served as control group.
Sample collection and processing
Rats were sacrificed by cervical dislocation under
deep anaesthesia with 10% chloral hydrate through
i.p. injection (300–350 mg/kg) in the fourteenth day
after CCI. Lumbar spinal cord segments L4–L5
were collected on ice and a small piece of the left
afferent nerve was kept to separate the left and
right side. Part of the collected samples was frozen
in liquid nitrogen for protein and RNA extraction,
and the left was fixed in 4% phosphate-buffered par-
aformaldehyde overnight, and then kept for dehy-
dration with gradient ethanol, incubated in 95, 70,
50 and 30% ethanol for 2 minutes, each sample was
then sliced into 3 mm thickness by RM135 micro-
tome.
Thermal and mechanical pain threshold
determination
Thermal pain threshold was determined by using
37370 radiant thermal stimulator. The rats were
placed on a thin glass platform. The radiant light
focussed on the pelma directly. The infrared (I.R.)
Intensity was 60% and the stimulating time was 20
seconds to avoid tissue damage. The paw withdrawal
thermal latencies (PWTL) were recorded automati-
cally. The mean latency was determined by five inde-
pendent tests excluding the maximum and minimum.
Mechanical pain threshold was assessed by the paw
withdrawal mechanical threshold (PWMT) in response
tomechanical stimuli by using 2390 vonFrey. Single rat
was placed in a transparent plastic cagewith awiremesh
bottom. The filaments were applied to the plantar sur-
face of the hind paw. The smallest filament eliciting
paw withdrawal was considered as the threshold. Five
trials with 5-minute intervals were applied for each
animal. The mean threshold was determined by five
trials except the maximum and minimum.
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Semi-quantitative analysis of GFAP
Motic professional series optical microscope was
used to obtain the images of glial fibrillary acidic pro-
tein (GFAP) expression after immunohistochemistry.
The GFAP positive areas and average densities were
assessed by Motic Image Advanced 3.0. The mean
positive areas and average densities were determined
by three different high quantitative (400|) regions
in one slide.
Statistical analysis
Datawas presented asmean+standard deviation (SD).
SPSS software was used to perform statistical analysis.
One-way ANOVA was use for comparison between
different groups. Pairwise comparison was conducted
by LSD and SNK-q test. Whereas, Student’s t-test was
used for comparisons within groups. P value less than
0.05 indicates significant difference.
Results
The changes of animals’ pain thresholds
We tested the thermal withdrawal latency and mech-
anical withdrawal threshold as indicators of pain
thresholds every other day after the CCI surgery
and 1 day before CCI. We found that the thermal
and mechanical withdrawal thresholds of CCI
group (Tables 1 and 2) were decreased from the
fourth day similar with those of the control groups.
However, thermal and mechanical withdrawal
thresholds of early-rapamycin group were signifi-
cantly increased comparing with those in CCI
group from day 4 to day 14 (Pv0.05) and thermal
and mechanical withdrawal thresholds of late-rapa-
mycin group had significant difference comparing
with those in CCI group since day 8 (Pv0.05).
These results indicated that mechanical and thermal
hyperalgesia emerged on fourth day and maintained
till fourteenth day after CCI operation and intrathe-
cal injection of rapamycin 4 hours or 7 days after
CCI could increase the mechanical and thermal
thresholds.
GFAP expressions in the spinal dorsal horn
We analysed the fluorescence densities of GFAP after
immunohistochemistry. We just injured the left side
sciatic nerve, thus the right side was regarded as con-
trol side. We found the GFAP positive areas and the
average densities were similar in the control side
(Pw0.05) (Table 3). The GFAP positive areas and
the average densities of injury side were significantly
increased in CCI group, early-rapamycin groups and
late-rapamycin groups comparing with those in con-
trol group, although the areas and densities were not
significantly different among CCI group, NS-early
and NS-late groups (Pw0.05). However, the
GFAP-positive areas and the average densities in
Rapamycin treatment groups with intrathecal injec-
tion of rapamycin 4 hours or 7 days after CCI were
significantly decreased than those in CCI group
(Pv0.05). Moreover, we found GFAP-positive area
in rats of late-rapamycin group was smaller than
that in early-rapamycin group (Pv0.05), while the
average densities was similar in both groups
(Pw0.05).
Table 2 Mechanical withdrawal threshold of all groups
Day 0 Day 2 Day 4 Day 6 Day 8 Day 10 Day 12 Day 14
Control 39.93+4.20 41.12+3.68 38.84+2.34 41.15+3.76 41.13+3.49 41.39+3.05 39.95+2.81 41.87+2.22
Chronic
constriction
injury(CCI)
39.51+2.97 36.17+2.04 19.98+1.97* 19.93+1.91* 17.42+1.39* 18.86+2.07* 20.06+2.62* 2.87+3.36*
ER 39.92+2.53 37.13+2.00 37.23+2.10 34.43+3.71 28.09+1.65 27.34+3.57 25.21+3.49 26.45+3.53
EV 39.97+2.15 35.59+3.36* 30.04+2.70* 20.42+2.28* 18.62+2.01* 18.36+1.72* 18.85+1.66* 21.16+3.44*
LR 40.37+2.96 36.53+2.19 29.86+3.40* 19.41+2.76* 26.40+3.13* 29.23+3.48* 28.99+2.98* 31.21+2.49*
LV 40.80+3.04 35.49+3.45 30.33+2.54 21.13+2.17* 19.87+2.91* 18.20+1.57* 17.65+2.16* 19.26+2.26*
Data were shown as mean+standard deviation (SD).ER: early rapamycin group; EV: early vehicle group; LR: late rapamycin group;
LV: late vehicle group. *Pv0.05 comparing with day 0; Pv0.05 comparing with CCI.
Table 1 Thermal withdrawal latency of all groups
Day 0 Day 2 Day 4 Day 6 Day 8 Day 10 Day 12 Day 14
Control 7.96+0.98 8.02+0.84 8.04+0.89 7.95+0.89 8.13+1.17 7.96+0.77 7.93+0.81 8.08+0.86
Chronic
constriction
injury(CCI)
8.06+0.97 7.35+0.84 4.92+0.66* 4.57+0.91* 4.06+0.59* 4.16+0.73* 4.29+0.71* 4.21+0.76*
ER 7.85+0.87 7.58+0.86 6.73+0.88 6.85+0.59 6.66+0.94 5.97+0.60* 6.51+0.73* 6.15+0.79*
EV 7.90+0.68 6.67+1.00* 5.13+0.79* 4.54+0.83* 3.88+0.67* 4.23+0.54* 4.09+0.93* 4.50+1.15*
LR 7.94+1.18 6.88+1.04 5.25+0.91* 4.15+1.06* 5.39+1.19* 5.82+0.91* 5.31+0.60* 5.41+0.90*
LV 8.22+1.04 6.84+0.64 5.27+0.81* 4.83+0.52* 4.37+0.84* 3.81+0.79* 4.21+0.95* 4.38+0.85*
Data was shown as mean+standard deviation (SD).ER: early-rapamycin group; EV: early-vehicle group; LR: late-rapamycin group;
LV: late-vehicle group. *Pv0.05 comparing with control; Pv0.05 comparing with CCI.
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Discussion
The present study showed that intrathecal injection
of rapamycin could alleviate increased mechanical
and thermal thresholds and activities of astrocytes
after CCI in rat models. Our study indicated the
function of mTOR during the development and
maintenance of neuropathic pain, this might provide
theoretical basis leading to new target in neuropathic
pain treatment.
Neuropathic pain may be caused by trauma or dis-
ease that affects the peripheral or central nerve system.
The symptoms included spontaneouspain, hyperalgesia
and allodynia. Widely used animal models for studying
the mechanisms of neuropathic pain are CCI, partial
sciatic nerve ligation (PSNL) and spinal nerve ligation
(SNL).13 chronic constriction injury model was first
reported by Bennette et al. in 1988, this model had
mimicked multiple features of clinic neuropathic
pain.11 In this study, we found after CCI surgery, the
thermalwithdrawal latency andmechanical withdrawal
thresholdof injure sidewere significantlydecreased than
those in control side (Tables 1 and2), and rats had lifting
and licking foot behaviour, these indicated that we have
successfully established the neuropathic pain model.
Mammalian target of rapamycin is a member of
phosphatidylinositol 3-kinases (PI3K) family. Recent
studies showed that mTOR regulated cell proliferation,
neuronal development and synaptic plasticity.4 When
activated by neurotrophic factor or hormone, mTOR
could have anti-apoptosis effect through regulating
the protein translation processing and phosphorylated
the downstream proteins.14 In this study, we intrathe-
cally administrated rapamycin, an mTORC1 inhibitor
within 4 hours after CCI surgery. Then, we monitored
rats’ pain thresholds, we found that in days 4–14 after
CCI surgery, rats receiving rapamycin treatment had
higher pain threshold than those of normal saline
administration. These indicated that intrathecal admin-
istration of rapamycin could decrease rats’ pain hyper-
sensitivity after CCI. Moreover, pharmacological
intervention before or during chronic neuropathic
pain also had the similar effect.
Glial cells can support neuronal function through
providing necessary nutrition. Moreover, glial cells
have important roles in formation and development
of neuropathic pain.15 Evidence showed that glial
cells in spinal cord could be activated during periph-
eral nerve injury or cancerous pain.16,17 In this study,
we found the activities of glia in rat’s spinal dorsal
horn have significantly increased. The immunohisto-
chemistry signal of GFAP was increased, mainly in
the first and second levels of spinal dorsal horn.
We observed that the cell bodies of astrocytes were
enlarged, the processes were thicker and longer and
the number was increased. These increased astro-
cytes’ activities were correlated with the decreased
pain threshold after CCI surgery. However, intrathe-
cal administration of rapamycin could increase the
mechanical withdrawal threshold and thermal with-
drawal latency. Simultaneously, the GFAP area
and average density were significantly decreased.
It indicated that the activities of astrocytes were
decreased. These results suggested that rapamycin
might decrease the pain hypersensitivity through
inhibiting astrocytes’ activities.
In conclusion, our study suggested that mTOR sig-
nalling had important role in the development of
neuropathic pain and intrathecal administration of
rapamycin could alleviate the symptom of neuro-
pathic pain. Thus, mTOR signalling might be thera-
peutic target for neuropathic pain.
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Table 3 Glial fibrillary acidic protein (GFAP) positive areas and densities (mean+SD)
Control
Chronic
constriction injury
(CCI) ER EV LR LV
Positive
areas(L)
57 836+5644.4 113 128+8286.5* 95 407+8247.5* 108 061+7995.9* 84 984+2459.5* 109 226+11 119.9*
Positive
areas(R)
60 271+5746.5 61 286+3609.9 60 623+4027.2 60 669+7775.1 60 805+5167.3 60 854+8656.8
Densities
(L)
0.2230+0.0014 0.2405+0.0019* 0.2269+0.0011* 0.2387+0.0016* 0.2276+0.0021* 0.2375+0.0012*
Densities
(R)
0.2219+0.0049 0.2294+0.0095 0.2217+0.0089 0.2349+0.0097 0.2206+0.0113 0.2204+0.0039
Data were shown as mean+standard deviation (SD).L: left; R: right; ER: early-rapamycin group; EV: early-vehicle group;
LR: late-rapamycin group; LV: late-vehicle group. *Pv0.05 comparing with day 0; Pv0.05 comparing with CCI.
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